| 注册
首页|期刊导航|中国药房|瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效和安全性比较

瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效和安全性比较

张理科 陈宇

中国药房2016,Vol.27Issue(12):1611-1613,3.
中国药房2016,Vol.27Issue(12):1611-1613,3.DOI:10.6039/j.issn.1001-0408.2016.12.09

瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效和安全性比较

Comparison of Efficacy and Safety of Rosuvastatin and Atorvastatin in the Treatment of Coronary Heart Dis-ease

张理科 1陈宇1

作者信息

  • 1. 杭州市第一人民医院,杭州 310000
  • 折叠

摘要

Abstract

OBJECTIVE:To compare the efficacy and safety of rosuvastatin and atorvastatin in the treatment of coronary heart disease. METHODS:96 patients with coronary heart disease were randomly divided into observation group and control group. All patients received reasonable diet control,low molecular weight heparin,Aspirin enteric-coated tablet,β-blockers,nitric acid lipids and other conventional treatment,but no vitamins and other antioxidant drugs. Based on it,observation group was orally given 10 mg Rosuvastatin tablet,once a day;control group was given 20 mg Atorvastatin capsule,once a day. The treatment course for both groups was 6 months. Clinical efficacy, total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C),high density lipoprotein cholesterol(HDL-C),high-sensitivity C-reactive protein(hs-CRP)and left ventricular ejection fraction (LVEF) before and after treatment,and the incidence of adverse reactions in 2 groups were observed. RESULTS:There were no significant differences in the total effective rate and incidence of adverse reactions between 2 groups(P>0.05). Before treat-ment,there were no significant differences in the TC,TG,LDL-C,HDL-C,hs-CRP and LVEF between 2 groups(P>0.05). After treatment,TC,TG,LDL-C,HDL-C and hs-CRP in 2 groups were significantly lower than before,and TC,LDL-C and hs-CRP in observation group were lower than control group,HDL-C and LVEF in 2 groups were significantly higher than before,and observa-tion group was higher than control group,the differences were statistically significant (P<0.05). CONCLUSIONS:Rosuvastatin and atorvastatin has similar efficacy and safety in the treatment of coronary heart disease,but rosuvastatin is superior to atorvastatin in terms of reducing lipid levels.

关键词

瑞舒伐他汀/阿托伐他汀/冠心病/疗效/安全性

Key words

Rosuvastatin/Atorvastatin/Coronary heart disease/Efficacy/Safety

分类

医药卫生

引用本文复制引用

张理科,陈宇..瑞舒伐他汀与阿托伐他汀治疗冠心病的疗效和安全性比较[J].中国药房,2016,27(12):1611-1613,3.

中国药房

OA北大核心CSTPCD

1001-0408

访问量0
|
下载量0
段落导航相关论文